Y-mAbs Therapeutics, Inc. (YMAB) News
Filter YMAB News Items
YMAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
YMAB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest YMAB News From Around the Web
Below are the latest news stories about Y-MABS THERAPEUTICS INC that investors may wish to consider to help them evaluate YMAB as an investment opportunity.
Y-mAbs Therapeutics Announces Strategic Business RealignmentThe latest update is out from Y-Mabs Therapeutics ( (YMAB) ). Y-mAbs Therapeutics announced a strategic business realignment to enhance operational flexibility and accelerate clinical development. The company will establish two business units focusing on radiopharmaceuticals and DANYELZA. This realignment includes a workforce reduction of up to 13% and relocation of roles from Denmark to the U.S. to optimize resources. The restructuring is expected to incur expenses of up to $2.6 million, impact |
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 PrioritiesCompany establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025 Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended Decem |
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business UnitNEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. “I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head,” said |
Y-mAbs Provides Strategic Business Update and 2025 PrioritiesCompany establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025 Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 3 |
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofABofA lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $14 from $17 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “increasingly areas of investo |
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at |
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ StocksIt’s safe to say that stock investors are closing out 2024 in a rather upbeat mood. The markets posted substantial gains, with the S&P 500 surging nearly 27% year-to-date. The support for the current bullish trend is clear. The prospect of interest rate cuts, coupled with stronger-than-expected corporate earnings, is driving market confidence. Adding to the bullish outlook, last month’s election saw former President Trump secure a non-consecutive second term, fueling hopes for a pro-business, pr |
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual MeetingNEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66th American Society of Hematology (ASH) Annual Meeting & Exposi |
Y-mAbs to Participate at Citi’s 2024 Global Healthcare ConferenceNEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that it will participate in Citi’s 2024 Global Healthcare Conference. Members of the Y-mAbs management team will host one-on-one meetings at the conference on Wednesday, December |